GlassScriptPhysician profile
Jamie Doone
NPI 1679133847
$4,916.15
in general payments reported to CMS, 2019-2025
37 companies · $742 in 2025
The $742 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,513 · 2022: $716 · 2023: $1,126 · 2024: $820 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.07 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $662.16 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $548.73 | 2021-2023 | Myrbetriq, Xtandi |
| Endo Pharmaceuticals INC. | $531.51 | 2021-2024 | Xiaflex, Aveed, Edex |
| Abbvie INC. | $282.55 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $277.21 | 2025 | Adstiladrin |
| Teleflex LLC | $257.89 | 2023-2025 | Urolift, Barrigel |
| Myovant Sciences INC. | $226.48 | 2021-2022 | |
| Angiodynamics, INC. | $201.03 | 2021 | |
| Janssen Biotech, INC. | $181.83 | 2021-2025 | Erleada |
| Endo USA, INC. | $149.12 | 2024-2025 | Xiaflex, Aveed |
| Medtronic, INC. | $138.47 | 2022-2023 | Interstim |
| Coloplast Corp | $136.02 | 2021-2024 | |
| Axonics, INC. | $130.36 | 2023-2024 | Bulkamid, Axonics |
| Tolmar Pharmaceuticals, INC. | $126.62 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.60 | 2021-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $80.82 | 2024-2025 | Illuccix |
| Acerus Pharmaceuticals Corporation | $75.92 | 2021 | |
| Stryker Corporation | $73.26 | 2024 | Actishield |
| Dendreon Pharmaceuticals LLC | $72.93 | 2021-2025 | Provenge |
| Sumitomo Pharma America, INC. | $69.24 | 2024 | Orgovyx, Gemtesa |
| Tolmar, INC. | $64.79 | 2023 | |
| Antares Pharma, INC. | $63.34 | 2021-2022 | |
| Allergan, INC. | $62.01 | 2021-2022 | |
| Clarus Therapeutics INC. | $50.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.02 | 2023-2025 | |
| Pfizer INC. | $45.36 | 2022-2023 | |
| Boston Scientific Corporation | $37.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.82 | 2021 | |
| 180 Medical, INC. | $28.89 | 2023 | |
| Foundation Medicine, INC. | $27.73 | 2023 | |
| Azurity Pharmaceuticals, INC. | $23.24 | 2025 | Azmiro |
| Ambu INC. | $22.90 | 2021 | |
| Urovant Sciences INC | $20.56 | 2022 | |
| Tempus Ai, INC | $19.95 | 2024 | |
| Progenics Pharmaceuticals, INC. | $15.56 | 2024 | |
| Mission Pharmacal Company | $13.67 | 2021 | |
| Dentsply Ih INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Doone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.